key: cord-0772469-wj778cj1 authors: Cassone, Antonio; Iacoviello, Licia; Cauda, Roberto title: Chloroquine/hydroxycloroquine and COVID-19: need to know more about date: 2020-11-16 journal: Future microbiology DOI: 10.2217/fmb-2020-0247 sha: 13aaed24e7d7900d0f515d7f3fd783c2f902b290 doc_id: 772469 cord_uid: wj778cj1 nan multicenter, nationwide studies have enrolled more than 10,000 hospitalized subjects with confirmed diagnosis of SARS-CoV-2 infection and treated with or without HCQ and standard supportive therapy as control. Cumulatively, around 7000 patients received HCQ at low (2400 mg) or moderate (maximum 4500 mg) dosage in almost 150 hospitals representing the whole hospital distribution over the national territory in Belgium and 33 centers in Italy, in other words, the major, biggest hospitals dealing with COVID-19 patients in the various Italian regions. Importantly, both studies reported a similar, substantial decrease of in-hospital mortality and no safety concerns in the HCQ-treated with respect to the mortality of HCQ-untreated, COVID-19 patients, after 13 days of follow-up (the Italian study) or until hospital discharge (24 days, the Belgian study). In a subgroup analysis of the Italian study which assessed HCQ effectiveness according to the level of a C-reactive protein on patient admission, a higher decrease of mortality in HCQ recipients with high level of this acute-phase inflammatory protein was detected [13] . The results of both studies do not allow a firm conclusion on the therapeutic efficacy of HCQ in COVID-19 patients because of the known ROS limitations, mainly their retrospective nature and the consequent lack of patient randomization. This bias cannot be totally eliminated by even extensive statistical corrections. This limitation being accounted for, the high number of treated patients and controls, coupled with careful data and subgroup analysis make the findings of these two studies quite valuable. They appear to be representative of a real world HCQ treatment of unselected, hospitalized patients as well as a faithful description of COVID-19 patients treated with HCQ in two European countries with high standards of public health and medical care. Although the data cannot be taken as indicators of a solid change in the future treatment of COVID-19, they should be considered for planning novel, well prepared and conducted RCT. In this scenario, and as relevant tool for planning future trials, we point out here the low -moderate total HCQ dosage used in the Belgian and Italian studies, respectively, and the limited time (5-7 days) of treatment. These dosages are much lower than those used in the aforementioned RCT, particularly a third of that used in the RECOVERY trial [17] . The choice of a loading dose of 800 mg the first day of treatment and a maintenance dose of 400 mg was based on previous reports about how balancing treatment efficacy and good safety profile, as from pharmacokinetics modeling [25, 26] . This is also the loading dose recommended for antimalarial treatment [25, 26] . In the Belgian study, the HCQ dosage was particularly low (2400 mg total), nonetheless, the COVID-19 mortality was reduced regardless of the timing from symptoms onset to diagnosis and initiation of HCQ treatment [24] . Literature examination of a critical aspect such as the HCQ dosing in COVID-19 patients does not seem particularly helpful as in many studies there appears to be a varied selection of drug dosage regimen without any attempt to justify or optimize it. Although the difficulties of estimating HCQ tissue levels from plasma concentrations are well known and have recently been highlighted [26, 27] , it remains unclear why in the RCT studies such a high dosage of HCQ was used. We assume it was selected in order to maximize the direct antiviral activity of the drug as this activity was realistically taken as rationale of HCQ trial (see above). Possibly, those high doses reached values that have favored emergence of side effects without achieving antiviral benefits. This matter is also greatly complicated by the number of different mechanisms that have been postulated to mediate CQ/HCQ activity, going from inhibition of one or more steps of SARS-CoV-2 replication to immunomodulatory and anti-inflammatory effects, likely each mechanism with a different dose-activity relationship [25] . Both ROS discussed above attribute the limited but substantial benefit of HCQ treatment of COVID-19 patients to the immunomodulatory rather than to the direct antiviral activity of HCQ that is unlikely achieved by the drug dosage used in those studies, unless to admit a synergistic effect between antiviral and immunomodulatory HCQ activities [25, 26] . Notably, anti-SARS-CoV-2 activity of HCQ, which has been largely confirmed in vitro with Vero cells [7, 8, 28] , was not found using pneumocytes, alveolar lung cell lines and some animal models [28, 29] . If immunomodulation/anti-inflammatory activity is the dominant or major mechanism of HCQ protection in COVID-19 patients, the high dosages used in the RCT studies could be unfit to stimulate a protective HCQ effect. In fact, nonsigmoidal, bell-shaped dose-response curves are not rare to obtain with drugs having complex immunomodulatory effects, with multiple-binding sites or cellular and organ targets, that just appears to be the case in point with CQ/HCQ. It remains highly speculative to assume that one of, or the reason for, the anti-COVID-19 activity of HCQ is the use of a low-moderate drug dosage because of the lack of large studies directly comparing low-moderate with high HCQ treatment doses. We have found only one small randomized, double-blind study where severely ill COVID-19 patients were treated with high (12 g) or low (2.7 g) chloroquine doses for 10 days, and their mortality compared [30] . In that study, the number of patients were low (81) and the difference in lethality was not considered 10 .2217/fmb-2020-0247 Future Microbiol. (Epub ahead of print) future science group to be statistically significant, nonetheless, 16 out of 41 and 6 out of 40 patients died in the high and low dosage group, respectively. Overall, the potential therapeutic or prophylactic activity of CQ/HCQ remains undetermined. The results of the numerous ongoing trials will possibly be of help. At any rate, it is our opinion that what we know so far, if correctly examined in all aspects and characteristics relevant to patients, HCQ usage and COVID-19 illness, would justify novel, correctly-designed and executed RCT, paying particular attention to the HCQ dosage and treatment duration. The abandonment of such a safe and cheap drug as HCQ would seem to be unjustified before new, knowledge-updated and oriented trials and until a specific, potent anti-SARS-CoV-2 therapeutic or vaccine becomes available. In essence, we still need to know more about CQ/HCQ and COVID-19. Pathophysiology and treatment strategies for COVID-19 Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors Effects of chloroquine on viral infections: an old drug against today's diseases? New insights into the antiviral effects of chloroquine In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Azithromycin in viral infections Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multicentre, randomized, controlled trial Effect of hydroxychloroquine in hospitalized patients with COVID-19 Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19 Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis No benefit of hydroxychloroquine in COVID-19: Results of systematic review and meta-analysis of randomized controlled trials Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project) Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants Chloroquine against malaria, cancers and viral diseases Hydroxychloroquine for treatment of SARS-CoV-2 infection? improving our confidence in a model-based approach to dose selection Population pharmacokinetics of hidroxychloroquine I COVID-19 patients: implications for dose optimization Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection a randomized clinical trial The authors are grateful to A Savarino (ISS, Rome, Italy) for updating us with recent prepublications and for many helpful discussions on chloroquine-hydroxychloroquine/COVID-19 state of art. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.